Article Information
History
- November 7, 2017.
Article Versions
- You are currently viewing Version 1 of this article (November 7, 2017 - 13:54).
- Version 2 (November 2, 2018 - 14:33).
- Version 3 (November 13, 2018 - 07:28).
- Version 4 (November 23, 2018 - 23:55).
- View Version 5, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Marc Hafner*1,
- Caitlin E. Mills*1,
- Kartik Subramanian1,
- Chen Chen1,
- Mirra Chung1,
- Sarah A. Boswell1,
- Robert A. Everley1,
- Charlotte S. Walmsley2,
- Dejan Juric1,2Φ and
- Peter K. Sorger1,†Φ
- 1Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115
- 2Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer, Center Boston, MA 02114
- ↵†Pre-publication correspondence should be addressed to Peter Sorger (peter_sorger{at}hms.harvard.edu); copying Marc Hafner (marchafner.hms{at}gmail.com).
↵* These authors contributed equally to this work.
↵Φ These authors contributed equally to this work.
Author contributions. MH, CEM, and DJ conceived the study; MH, CEM, DJ, and PKS designed the experiments and CEM, MC, SAB, and RAE performed them. MH, KS, and CC performed the computational analyses. CSW and DJ obtained the patient-derived line and provided related data. PKS oversaw the experimental and computational research; MH, CEM, KS, DJ, and PKS wrote the manuscript.